EGFR+ Lung Cancer

>

Latest News

FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC

November 14th 2024

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.

FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC
FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC

September 20th 2024

Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment
Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment

September 11th 2024

Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer

August 20th 2024

Latest CME Events & Activities

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Annual Hawaii Cancer Conference

January 25-26, 2025

Register Now!

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

More News

Denise O'Dea, NP: Managing Adverse Events Such as Rash and Stomatitis

Denise O'Dea, NP: Managing Adverse Events Such as Rash and Stomatitis

October 22nd 2015

Watch

Denise O'Dea, NP: Concern About Potential Drug Interactions

Denise O'Dea, NP: Concern About Potential Drug Interactions

October 22nd 2015

Watch

Denise O'Dea, NP: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

Denise O'Dea, NP: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

October 22nd 2015

Watch

Corey J. Langer, MD: Options for Treatment and Reimbursement

Corey J. Langer, MD: Options for Treatment and Reimbursement

October 22nd 2015

Watch

Corey J. Langer, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

Corey J. Langer, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

October 22nd 2015

Watch

Corey J. Langer, MD: Managing Adverse Events Such as Rash and Stomatitis

Corey J. Langer, MD: Managing Adverse Events Such as Rash and Stomatitis

October 22nd 2015

Watch

Corey J. Langer, MD: Concern About Potential Drug Interactions

Corey J. Langer, MD: Concern About Potential Drug Interactions

October 22nd 2015

Watch

Corey J. Langer, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

Corey J. Langer, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

October 22nd 2015

Watch

David Spigel, MD: Options for Treatment and Reimbursement

David Spigel, MD: Options for Treatment and Reimbursement

October 22nd 2015

Watch

David Spigel, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

David Spigel, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

October 22nd 2015

Watch

David Spigel, MD: Managing Adverse Events Such as Rash and Stomatitis

David Spigel, MD: Managing Adverse Events Such as Rash and Stomatitis

October 22nd 2015

Watch

David Spigel, MD: Concern About Potential Drug Interactions

David Spigel, MD: Concern About Potential Drug Interactions

October 22nd 2015

Watch

David Spigel, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

David Spigel, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

October 22nd 2015

Watch

Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 1

Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 1

October 22nd 2015

Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD

Watch

Jack West, MD: Options for Treatment and Reimbursement After Dose Reduction

Jack West, MD: Options for Treatment and Reimbursement After Dose Reduction

October 22nd 2015

Watch

Jack West, MD: Concern About Drug Interactions

Jack West, MD: Concern About Drug Interactions

October 22nd 2015

Watch

Jack West, MD: Clinical Criteria for Dose Reduction

Jack West, MD: Clinical Criteria for Dose Reduction

October 22nd 2015

Watch

Jack West, MD: Recommendations for Managing the Principle Adverse Event of Diarrhea

Jack West, MD: Recommendations for Managing the Principle Adverse Event of Diarrhea

October 22nd 2015

Watch

Jack West, MD: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLC

Jack West, MD: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLC

October 22nd 2015

Watch

Denise O'Dea: Options for Treatment and Reimbursement After Dose Reduction

Denise O'Dea: Options for Treatment and Reimbursement After Dose Reduction

October 22nd 2015

Watch

Denise O'Dea, NP: Concern About Drug Interactions

Denise O'Dea, NP: Concern About Drug Interactions

October 22nd 2015

Watch

Denise O'Dea, NP: Clinical Criteria for Dose Reduction

Denise O'Dea, NP: Clinical Criteria for Dose Reduction

October 22nd 2015

Watch

Denise O'Dea, NP: Recommendations for Managing the Principle Adverse Event of Diarrhea

Denise O'Dea, NP: Recommendations for Managing the Principle Adverse Event of Diarrhea

October 22nd 2015

Watch

Denise O'Dea, NP: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLC

Denise O'Dea, NP: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLC

October 22nd 2015

Watch

Corey J. Langer, MD: Options for Treatment and Reimbursement After Dose Reduction

Corey J. Langer, MD: Options for Treatment and Reimbursement After Dose Reduction

October 22nd 2015

Watch

Corey J. Langer, MD: Concern About Drug Interactions

Corey J. Langer, MD: Concern About Drug Interactions

October 22nd 2015

Watch

Corey J. Langer, MD: Clinical Criteria for Dose Reduction

Corey J. Langer, MD: Clinical Criteria for Dose Reduction

October 22nd 2015

Watch

Corey J. Langer, MD: Recommendations for Managing the Principle Adverse Event of Diarrhea

Corey J. Langer, MD: Recommendations for Managing the Principle Adverse Event of Diarrhea

October 22nd 2015

Watch

Corey J. Langer, MD: Use of TKI Therapy in Patients With EGRF Exon 19 Deletion NSCLC

Corey J. Langer, MD: Use of TKI Therapy in Patients With EGRF Exon 19 Deletion NSCLC

October 22nd 2015

Watch

David Spigel, MD: Options for Treatment and Reimbursement After Dose Reduction

David Spigel, MD: Options for Treatment and Reimbursement After Dose Reduction

October 22nd 2015

Watch

<1
...
454647484950515253
...
60>